RET fusions in solid tumors
Andrew Y. Li(University of Maryland, Baltimore), Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Katherine A. Scilla(University of Maryland, Baltimore), Ranee Mehra(Fox Chase Cancer Center), Vincenzo Adamo(University of Messina), Katherine E. Arensmeyer(University of Maryland, Baltimore), Alessandro Russo(University of Messina), Michael G. McCusker(University of Maryland, Baltimore), Allison Gittens(University of Maryland, Baltimore)
Cited by 251
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642